ISDA

Deposition Date 2022-08-15

Release Date 2022-11-16

Last Version Date 2024-10-16

Entry Detail

PDB ID:

8E2M

Keywords:

TRANSFERASE

Title:

Bruton's tyrosine kinase (BTK) with compound 13

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.90 Å

R-Value Free:

0.19

R-Value Work:

0.15

R-Value Observed:

0.15

Space Group:

P 2 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase BTK
Gene (Uniprot):BTK
Chain IDs:A
Chain Length:271
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q06187 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

PGE

UB6

Primary Citation

Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Tichenor, M.S, Wiener, J.J.M, Rao, N.L, Bacani, G.M, Wei, J, Pooley Deckhut, C, Barbay, J.K, Kreutter, K.D, Chang, L, Clancy, K.W, Murrey, H.E, Wang, W, Ahn, K, Huber, M, Rex, E, Coe, K.J, Wu, J, Rui, H, Sepassi, K, Gaudiano, M, Bekkers, M, Cornelissen, I, Packman, K, Seierstad, M, Xiouras, C, Bembenek, S.D, Alexander, R, Milligan, C, Balasubramanian, S, Lebsack, A.D, Venable, J.D, Philippar, U, Edwards, J.P, Hirst, G.Show

J.Med.Chem. 65 14326 14336 (2022)

PMID: 36314537 DOI: 10.1021/acs.jmedchem.2c01026

Abstact

Bruton's tyrosine kinase (BTK) is a Tec family kinase that plays an essential role in B-cell receptor (BCR) signaling as well as Fcγ receptor signaling in leukocytes. Pharmacological inhibition of BTK has been shown to be effective in treating hematological malignancies and is hypothesized to provide an effective strategy for the treatment of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. We report the discovery and preclinical properties of JNJ-64264681 (13), a covalent, irreversible BTK inhibitor with potent whole blood activity and exceptional kinome selectivity. JNJ-64264681 demonstrated excellent oral efficacy in both cancer and autoimmune models with sustained in vivo target coverage amenable to once daily dosing and has advanced into human clinical studies to investigate safety and pharmacokinetics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures